The field of radiation oncology has made tremendous technological progress in the last 30 years, with the development of new software and hardware that integrate the latest tumor imaging modalities with highly precise radiation delivery methods. These technical advances include intensity-modulated radiotherapy (IMRT), imageguided radiotherapy (IGRT), stereotactic body or ablative radiotherapy (SBRT/SABR) and particle-beam therapy (proton and carbon ion). Accordingly, patients with solid tumors enjoy higher rates of local tumor control and fewer side effects than ever before. However, with rapid technological advances comes the burden of cost escalation. In addition, systemic therapies continue to evolve independent of radiotherapy, posing the challenge of how to integrate these modalities together. Swift introduction of new drugs and technologies also poses the major challenge of how to test them in clinical trials that can keep pace with evolving changes without being outdated by the time of result reporting, while minimizing escalating cost.
One suggested approach is to use 'Big Data' to guide clinical practice and potentially to replace clinical trials in certain settings. Initiatives are ongoing across the globe to examine how Big Data can be used to diagnose and treat pathologic conditions, including cancer. Within radiation oncology, innovations in data processing and storage have led to collections of large biological, imaging, dosimetric and clinical datasets that can be exploited to test the effectiveness as well as the cost-benefit ratio of new technologies such as SBRT/SABR or particle-beam therapy. However, for best use of Big Data, the data has to be of large volume, well curated and collected from a diverse patient population treated at different institutions. In order for that to happen, there needs to be international consensus on how data are collected and curated in databases, how they are analyzed, what model is best for reflecting efficacy and toxicity, how these models represent actual biological processes, and how they can complement ongoing clinical trials. After an overview of these approaches by University last year about how to develop a consensus model-based approach to particle-beam therapy. Panelists included representatives from the USA, Japan, and the Netherland, with the last country being where the national government has approved the use of a model-based approach as the basis for reimbursement of protonbeam therapy.
We hope that this special issue can provide valuable information for better understanding of the current approaches used in selecting advanced external beam radiotherapy.
